September 29th - October 3rd, 2006 / Istanbul, Turkey Determinants of cetuximab reversal of resistance to chronomodulated chemotherapy as 4th line treatment of metastatic colorectal cancer. Lévi F., Karaboué A., Bralet M.P., Innominato P., Moreau T., Herelle M.O., Hauteville D., Adam R., Guettier C., Bouchahda M. Ann. Oncol., 2006: 17 (9), suppl 358.
lire la suite
September 28th – October 2nd, 2012 / Vienna, Austria
September 28th – October 2nd, 2012 / Vienna, Austria Robustness of circadian rest-activity rhythm for predicting the antitumor efficacy of intravenous cetuximab and hepatic artery infusion of chronomodulated Irinotecan, 5-Fluorouracil and Oxaliplatin for colorectal cancer liver metastases. An OPTILIV companion study. A. Karaboue, P. Innominato, M. Bouchahda, M. Mocquery, R. Bossevot, V. Plessis, D. Bouchoucha,…
lire la suite
25 – 29 September 2015 / Austria, Vienna
25 - 29 September 2015 / Austria, Vienna Use of Early tumor shrinkage to as a predictor forpredict long-term outcome in patients with unresectable liver metastases from wt-KRAS colorectal cancer treated with hepatic artery infusion of Irinotecan, 5-Fluorouracil and Oxaliplatine plus intravenous Cetuximab after failure of one to three systemic protocols (European phase II clinical…
lire la suite